| Primary | In-stent Late Loss (LL) | This is the primary angiographic endpoint. In-stent LL: The difference between the minimum lumen diameter (MLD) immediately after stent deployment and the MLD at follow-up (within stent) | The number of participants with angiographic follow up available was analysed. | Posted | | Mean | Standard Deviation | Millimeter | | >=13 months | Lesions | Participants | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| | Units | Counts |
|---|
| Participants | | | Lesions | |
| | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG0000.19± 0.28
- OG0010.21± 0.28
|
|
| |
| Primary | Ischemia-driven Target Vessel Failure (ID-TVF) | This is the primary efficacy endpoint. Ischemia-driven target vessel failure is defined as the composite of cardiac death, all myocardial infarction (MI) and ischemia-driven target vessel revascularization (ID-TVR). | The number of participants with angiographic follow up available was analysed. | Posted | | Number | 95% Confidence Interval | percentage of participants | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Primary | Incidence of Composite of ST (Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non-Q-wave) | The primary composite safety endpoint was the incidence of the composite of ST (definite and probable), all death (cardiac, vascular and non-cardiovascular), and all MI (including Q-wave and non-Q-wave). | The number of participants with angiographic follow up available was analysed. | Posted | | Number | 95% Confidence Interval | percentage of participants | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Ischemia-driven Target Vessel Failure (ID-TVF) | Incidence of composite of cardiac death, all MI (including Q-wave and non- Q-wave), and ID target vessel revascularization (ID-TVR) (TLR and non-TLR in the TV [PCI and CABG]) | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 30 days | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Ischemia-driven Target Vessel Failure (ID-TVF) | Incidence of composite of cardiac death, all MI (including Q-wave and non- Q-wave), and ID target vessel revascularization (ID-TVR) (TLR and non-TLR in the TV [PCI and CABG]). | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 6 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Ischemia-driven Target Vessel Failure (ID-TVF) | Incidence of composite of cardiac death, all MI (including Q-wave and non- Q-wave), and ID target vessel revascularization (ID-TVR) (TLR and non-TLR in the TV [PCI and CABG]) | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 9 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Ischemia-driven Target Vessel Failure (ID-TVF) | Incidence of composite of cardiac death, all MI (including Q-wave and non- Q-wave), and ID target vessel revascularization (ID-TVR) (TLR and non-TLR in the TV [PCI and CABG]) | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Incidence of Composite of Stent Thrombosis (ST)(Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non-Q-wave). | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 30 days | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Incidence of Composite of Stent Thrombosis (ST)(Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non-Q-wave). | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 6 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Incidence of Composite of Stent Thrombosis (ST)(Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non-Q-wave) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 9 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Incidence of Composite of Stent Thrombosis (ST)(Definite and Probable), All Death (Cardiac, Vascular and Non-cardiovascular), and All MI (Including Q-wave and Non-Q-wave) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Ischemia-driven Target Lesion Revascularization (ID-TLR) (Percutaneous Coronary Intervention [PCI] and Coronary Artery Bypass Graft [CABG]) | The is the major Secondary Efficacy Endpoint. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | 95% Confidence Interval | percentage of participants | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Ischemia-driven Target Lesion Failure (ID-TLF) | Incidence of composite of cardiac death, MI attributed to the TV and ID-TLR | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 30 days | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Ischemia-driven Target Lesion Failure (ID-TLF) | Incidence of composite of cardiac death, MI attributed to the TV and ID-TLR | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 6 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Ischemia-driven Target Lesion Failure (ID-TLF) | This is one of the Secondary Composite Endpoints. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 9 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Ischemia-driven Target Lesion Failure (ID-TLF) | This is one of the Secondary Composite Endpoints. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Ischemia-driven Target Lesion Failure (ID-TLF) | This is one of the Secondary Composite Endpoints. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non-Q-wave) Attributed to the Target Vessel (TV) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 30 days | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non-Q-wave) Attributed to the Target Vessel (TV) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 6 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non-Q-wave) Attributed to the Target Vessel (TV) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 9 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non-Q-wave) Attributed to the Target Vessel (TV) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Incidence of Composite of Cardiac Death and MI (Including Q-wave and Non-Q-wave) Attributed to the Target Vessel (TV) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG) | This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].](streamdown:incomplete-link) | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 30 days | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG) | This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].](streamdown:incomplete-link) | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 6 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG) | This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].](streamdown:incomplete-link) | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 9 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG) | This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].](streamdown:incomplete-link) | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Death(Cardiac, Vascular and Non-cardiovascular), All MI, All Revascularization (TLR, TVR, and Non-TVR) (PCI and CABG) | This is one of the Secondary Composite Endpoint. All death(cardiac, vascular and non-cardiovascular), all MI, all revascularization [(target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target lesion revascularization(TVR) [Percutaneous coronary intervention (PCI) and Coronary artery bypass graft(CABG)].](streamdown:incomplete-link) | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 30 days | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 6 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 9 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Incidence of Composite of All Death (Cardiac, Vascular and Non-cardiovascular) and All MI | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Major Adverse Cardiac Event (Cardiac Death, All MI and TLR) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 30 days | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Major Adverse Cardiac Event (Cardiac Death, All MI and TLR) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 6 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Major Adverse Cardiac Event (Cardiac Death, All MI and TLR) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 9 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Major Adverse Cardiac Event (Cardiac Death, All MI and TLR) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Major Adverse Cardiac Event (Cardiac Death, All MI and TLR) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Revascularization (TLR, TVR, and Non-TVR) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 30 Days | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Revascularization (TLR, TVR, and Non-TVR) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 6 Months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Revascularization (TLR, TVR, and Non-TVR) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 9 Months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Revascularization (TLR, TVR, and Non-TVR) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Revascularization (TLR, TVR, and Non-TVR) | One of the Secondary Safety Endpoint was all revascularization rates (target lesion, target vessel, non-target lesion, and non-target vessel) (PCI and CABG). | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Death | This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 30 days | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Death | This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 6 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Death | This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 9 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Death | This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Death | This is one of the secondary safety endpoint. All Death includes cardiac, vascular, non-cardiovascular. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Protocol MI (Including Q-wave or Non-Q-wave) | This is one of the secondary safety endpoint. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 30 days | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Protocol MI (Including Q-wave or Non-Q-wave) | This is one of the secondary safety endpoint. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 6 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Protocol MI (Including Q-wave or Non-Q-wave) | This is one of the secondary safety endpoint. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 9 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Protocol MI (Including Q-wave or Non-Q-wave) | This is one of the secondary safety endpoint. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | All Protocol MI (Including Q-wave or Non-Q-wave) | This is one of the secondary safety endpoint. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Target Vessel Protocol MI (TV-MI) | This is one of the secondary safety endpoint. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 30 days | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Target Vessel Protocol MI (TV-MI) | This is one of the secondary safety endpoint. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 6 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Target Vessel Protocol MI (TV-MI) | This is one of the secondary safety endpoint. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 9 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Target Vessel Protocol MI (TV-MI) | This is one of the secondary safety endpoint. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Target Vessel Protocol MI (TV-MI) | This is one of the secondary safety endpoint. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Major Bleeding Complications | Secondary safety endpoint. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 30 days | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Major Bleeding Complications | Secondary safety endpoint. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 6 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Major Bleeding Complications | Secondary safety endpoint. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 9 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Major Bleeding Complications | Secondary safety endpoint. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Major Bleeding Complications | Secondary safety endpoint. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Definite / Probable Stent Thrombosis | Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | Acute (<1 day) | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Definite / Probable Stent Thrombosis | Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | Subacute (1 - 30 days) | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Definite / Probable Stent Thrombosis | Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | Early (0 - 30 days) | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Definite / Probable Stent Thrombosis | Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | Late (31 - 365 days) | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Definite / Probable Stent Thrombosis | Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | Very late (366 - 772 days) | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Definite / Probable Stent Thrombosis | Stent Thrombosis was adjudicated using Academic Research Consortium (ARC) criteria. Definite Stent Thrombosis defined as angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic changes suggestive of acute ischemia, typical rise and fall of cardiac biomarkers; pathological confirmation of ST through either autopsy or tissue examination following thrombectomy. Probable Stent Thrombosis defined as any unexplained death within the first 30 days or, irrespective of the time after the index procedure, any MI related to documented acute ischemia in the territory of the stent without angiographic confirmation. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | Overall (0 - 772 days) | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Patient Compliance With Dual Antiplatelet Therapy (DAPT) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 30 days | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Patient Compliance With Dual Antiplatelet Therapy (DAPT) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 6 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Patient Compliance With Dual Antiplatelet Therapy (DAPT) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 9 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Patient Compliance With Dual Antiplatelet Therapy (DAPT) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Patient Compliance With Dual Antiplatelet Therapy (DAPT) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Acute Device Success | Per-protocol device success is defined as the achievement of a final in-stent residual diameter stenosis (DS) of < 50% by Quantitative Coronary Angiography (QCA), using only the assigned device, and occurring without a device malfunction. | | Posted | | Number | | percentage of participants | | < or = 1 day | Target lesions | Participants | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Acute Procedure Success | Per-protocol procedure success is defined as the achievement of a final in-stent DS of < 50% (by online QCA or visual estimation), using the assigned device and with any adjunctive devices, and occurring without cardiac death, MI (including Q-wave or non-Q-wave), or repeat revascularization of the target lesion during the hospital stay. | | Posted | | Number | | percentage of participants | | < or = 1 day | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Procedure Time | This is the procedure related endpoint. Procedure time is defined as time between insertion of the first guiding catheter until removal of the last guiding catheter. | | Posted | | Median | Standard Deviation | Minutes | | On day 0, during the procedure. | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Amount of Contrast Used | Defined as total amount used from insertion of the first guiding catheter until removal of the last guiding catheter. | | Posted | | Median | Standard Deviation | Milliliter | | On day 0, during the procedure. | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Fluoroscopy Time | This is the procedure related endpoint. | | Posted | | Median | Standard Deviation | Minutes | | On day 0, during the procedure. | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | XIENCE V EECSS Excellent Overall Performance and Deliverability Using the XIENCE V EECSS Performance Evaluation Questionnaire | A related secondary performance goal for XIENCE V EECSS is the physician-determined evaluation of acute performance, deliverability, and resource utilization. XIENCE V EECSS acute performance and deliverability were determined using the XIENCE V EECSS Performance Evaluation Questionnaire. Possible responses included strongly agree,moderately agree, agree, moderately disagree, and strongly disagree. Study physicians who enrolled patients into the study were reported for this outcome measure. | | Posted | | Number | | percentage of participants | | During the procedure | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. |
| |
| Secondary | Follow-up Late Loss | This is one of the Secondary Angiographic Endpoint. | The number of participants with angiographic follow up available was analysed. | Posted | | Mean | Standard Deviation | Millimeter | | ≥13 months. | Target lesions | Participants | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Follow-up In-stent Minimum Lumen Diameter (MLD) | | The number of participants with angiographic follow up available was analysed. | Posted | | Mean | Standard Deviation | Millimeter | | ≥13 months | Target lesions | Participants | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Follow-up In-stent Percent Diameter Stenosis (DS) | | The number of participants with angiographic follow up available was analysed. | Posted | | Mean | Standard Deviation | percent Diameter stenosis | | ≥13 months | Target lesions | Participants | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Follow-up In-stent Angiographic Binary Restenosis (ABR) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | ≥13 months | Target lesions | Participants | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Follow-up In-segment Minimum Lumen Diameter (MLD) | | The number of participants with angiographic follow up available was analysed. | Posted | | Mean | Standard Deviation | Millimeter | | ≥13 months | Target lesions | Participants | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Follow-up In-segment Percent Diameter Stenosis (DS) | | The number of participants with angiographic follow up available was analysed. | Posted | | Mean | Standard Deviation | percent Diameter stenosis | | ≥13 months | Target lesions | Participants | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Follow-up In-segment Angiographic Binary Restenosis (ABR) | | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | ≥13 months | Target lesions | Participants | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Percent Diameter Stenosis | | The number of participants with angiographic follow up available was analysed. | Posted | | Mean | Standard Deviation | percent Diameter stenosis | | pre procedure | Target lesions | Participants | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Percent Diameter Stenosis (%DS) | | The number of participants with angiographic follow up available was analysed. | Posted | | Mean | Standard Deviation | Percent Diameter stenosis | | post procedure on 0 day | Target lesions | Participants | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Secondary | Acute Gain | | The number of participants with angiographic follow up available was analysed. | Posted | | Mean | Standard Deviation | Millimeter | | post procedure on 0 day | Target lesions | Participants | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | ID-TVF Rate in Patients With Diabetic Disease | ID-TVF rate in All Diabetes patients. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | ID-TVF Rate in Patients Without Diabetic Disease | ID-TVF rate in Non Diabetes | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | ID-TVF Rate in Single Lesion Treated Subgroup | ID-TVF rate in Patients with single lesion treated during the index procedure | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | ID-TVF Rate in Dual Lesion Treated Subgroup | ID-TVF rate in Patients with dual lesion treated during the index procedure | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | ID-TVF Rate in Single Vessel Treated Subgroup | ID-TVF rate in Patients with single vessels treated during the index procedure. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | ID-TVF Rate in Dual Vessel Treated Subgroup | ID-TVF rate in Patients with dual vessel treated during the index procedure. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | The Composite of ST, All Death, and All MI Rate in Patients With Diabetic Disease. | The composite of ST, all death, and all MI rate in All Diabetes patients. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | The Composite of ST, All Death, and All MI Rate in Patients Without Diabetic Disease | The composite of ST, all death, and all MI rate in Non Diabetes | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | The Composite of ST, All Death, and All MI Rate in Single Lesion Treated Subgroup | The composite of ST, all death, and all MI rate in Patients with single lesion treated during the index procedure | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | The Composite of ST, All Death, and All MI Rate in Dual Lesion Treated Subgroup | The composite of ST, all death, and all MI rate in Patients with dual lesion treated during the index procedure | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | The Composite of ST, All Death, and All MI Rate in Single Vessel Treated Subgroup | The composite of ST, all death, and all MI rate in Patients with single vessels treated during the index procedure. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | The Composite of ST, All Death, and All MI Rate in Dual Vessel Treated Subgroup | The composite of ST, all death, and all MI rate in Patients with dual vessel treated during the index procedure. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | ID-TLR Rate in Patients With Diabetic Disease. | Ischemia-driven target lesion revascularization rate in All Diabetes patients. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | ID-TLR Rate in Patients Without Diabetic Disease | Ischemia-driven target lesion revascularization rate in Non Diabetes | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | ID-TLR Rate in Single Lesion Treated Subgroup | Ischemia-driven target lesion revascularization rate in Patients with single lesion treated during the index procedure | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | ID-TLR Rate in Dual Lesion Treated Subgroup | Ischemia-driven target lesion revascularization rate in Patients with dual lesion treated during the index procedure | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | ID-TLR Rate in Single Vessel Treated Subgroup | Ischemia-driven target lesion revascularization rate in Patients with single vessels treated during the index procedure. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |
| Other Pre-specified | ID-TLR Rate in Dual Vessel Treated Subgroup | Ischemia-driven target lesion revascularization rate in Patients with dual vessel treated during the index procedure. | The number of participants with angiographic follow up available was analysed. | Posted | | Number | | percentage of participants | | 24 months | | | | ID | Title | Description |
|---|
| OG000 | XIENCE V EECSS | Patients who will receive this stent. XIENCE V EECSS: Patients who will receive this stent. | | OG001 | CYPHER SELECT PLUS SECSS | Patients who will receive this stent. CYPHER SELECT PLUS SECSS: Patients who will receive this stent. |
| |